Literature DB >> 2143464

Comparison of clinical and experimental uveitis.

J V Forrester1, J Liversidge, H S Dua, H Towler, P G McMenamin.   

Abstract

Uveitis is a term which encompasses many clinical syndromes which would appear to be discrete entities. Both clinically and experimentally, the separation of uveitis affecting only the anterior segment from that affecting the posterior segment has a sound pathogenetic basis. However, clear distinctions among the various forms of endogenous posterior uveitis are more difficult to maintain in the light of evidence from experimental models of autoimmune uveitis (EAU). EAU can be induced by a variety of retinal antigens and each antigen has been shown to induce somewhat different forms of EAU, depending on such factors as dose of antigen, species and strains of animal model, and the type(s) of adjuvant used. However, within each model a similar spectrum of uveoretinal responses can be induced by each antigen suggesting that the pathogenetic mechanisms are probably similar also. In addition, if these models are analogous to human disease, then each clinical entity within this apparently heterogeneous group of clinical posterior uveitis syndromes may represent one aspect of a general organ-specific uveoretinal response to autoantigens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143464     DOI: 10.3109/02713689008999424

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  37 in total

Review 1.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerance therapy.

Authors:  A D Dick; V Sharma; J Liversidge
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

Review 3.  Tolerance and autoimmunity in the eye: a role for CD8 T cells in organ-specific autoimmunity in the retina.

Authors:  John V Forrester; Richard J Cornall
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

Review 4.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

5.  Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation.

Authors:  Alfonso Giovannini; Piergiorgio Neri; Lucia Mercanti; Claudia Bruè
Journal:  Br J Ophthalmol       Date:  2007-01-03       Impact factor: 4.638

6.  Ultrastructural pathology of the 'barrier sites' in experimental autoimmune uveitis and experimental autoimmune pinealitis.

Authors:  H S Dua; A McKinnon; P G McMenamin; J V Forrester
Journal:  Br J Ophthalmol       Date:  1991-07       Impact factor: 4.638

7.  Diverse roles of natural killer T lymphocytes in liver and spleen in mice with experimental autoimmune uveitis.

Authors:  Shengya Zhao; Dadong Guo; Hongsheng Bi; Yan Cui; Xiaofeng Xie; Xingrong Wang; Jiao Li
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

Review 8.  Endogenous posterior uveitis.

Authors:  J V Forrester
Journal:  Br J Ophthalmol       Date:  1990-10       Impact factor: 4.638

9.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

10.  Comparison of the expression of interferon gamma, IL2, IL4, and lymphotoxin mRNA in experimental autoimmune uveoretinitis.

Authors:  D G Charteris; S L Lightman
Journal:  Br J Ophthalmol       Date:  1994-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.